Key Takeaways
- Volume and price both up, driving strong revenue: Volume grew ~8.5% YoY while realizations jumped 25% YoY, a combination of grade mix, freight pass-through and a weaker rupee.
- Margins dipped on new venture costs: EBITDA margin declined as the nascent OTC and nutritional businesses contributed costs without meaningful revenue yet; management expects to sustain margins above 20–21% going forward.
- Brownfield expansion on track for Q4: 7,000 MT of new MCC capacity is expected to commission in Q4 FY23, with sales beginning in Q1 FY24 and a two-to-three-year absorption timeline.
- Diversification bets are early and unproven: Nutraceutical revenue guidance was cut to ₹12–15 Cr for H2, the CCS plant is 18–24 months from revenue, and the OTC healthcare launch is still building distribution.
- What to watch next quarter: Whether the Q3 price increase lands with customers, the pace of new MCC capacity commissioning, and any concrete revenue from the nutritional premix facility.
Revenue & Realization Drivers
- Volume growth steady: Q2 sales volume was ~3,500 metric tons, with H1 sales volume at 6,823 metric tons, reflecting ~8.5% volume growth driven by increased MCC demand across all industries.
- Realization jump was multi-factor: The 25% YoY increase came from product mix shifts toward specialized grades, the pass-through of elevated freight costs, and a depreciated rupee, not any single lever.
- QoQ pricing flat: Average price moved only marginally from ₹216.75 in Q1 to ₹217.04 in Q2, suggesting the YoY jump was already embedded by Q1.
- Price increase signaled for Q3: Some customers will see a single-digit price rise in Q3; management does not expect further increases beyond that unless crude oil or raw material prices shift significantly.
- Export momentum strong: Export sales grew 40% to ₹113.2 Cr in H1 FY23 vs ₹80.87 Cr in H1 FY22, with most exports on a CIF basis.
- Demand resilience thesis: Management argues the pharmaceutical industry is technically recession-proof, citing no demand drop during the 2008 crisis and no current slowdown visible in international markets despite recession talk.
Amit Raj Sinha: "I am sure you would believe that currently the prices are most of the prices are already at its peak. So, we do not see further price being going up. However, in case there is significant change in the crude oil or in the raw material prices we would not really hesitate in passing on the price."
Margin Structure & Cost Trends
- New ventures dragged margins: The EBITDA margin decline was attributed to costs from the OTC healthcare and nutritional businesses, both in nascent launch stages with low current margin contribution.
- Freight costs easing: Freight cost has been dropping over the last couple of months, though management is observing cautiously and declined to quantify the decline on a percentage basis, citing variability by destination.
- Raw material costs moderating: Raw material cost was at ~$900–$950 in Q2 and is expected to come down a little, with crude oil and some input prices in a declining phase.
- Depreciation spike explained: Quarterly depreciation jumped from ~₹80 lakhs to ~₹2.1 Cr due to the nutraceutical plant taken on lease; under lease accounting, the initial-year expense is higher because all lease rentals are brought to NPV and a finance cost is charged.
- Tax rate benefit temporary: Q2 tax rate fell to 11% due to deferred tax assets/liabilities from ongoing CAPEX; this lower rate is expected to continue for another 4 years until the SEZ exemption lapses, after which the rate will increase by 3–4%.
- Margin floor commitment: Management expressed confidence in maintaining EBITDA margins above 20–21% irrespective of realization decreases, though absolute EBITDA would be impacted if realizations drop.
Amit Raj Sinha: "I am very comfortable or very confident on maintaining our margins even if the realizations drop the comfort and confident of maintaining our margins remains intact. ... if I have been higher than 20% EBITDA I would continue to see that I am a 20%, 21% EBITDA all throughout irrespective of our decrease in our realization or increase in our realizations."
Capacity Expansion & Utilization
- Brownfield MCC expansion timeline: 7,000 MT of additional capacity at Dahej and Jhagadia is expected to be ready by end of FY23, with commissioning in Q4 FY23 and sales starting in Q1 FY24.
- Absorption pace uncertain: Management stands by its earlier indication of full utilization over two years but acknowledges the timeline could extend to three years due to external variables like market changes and ocean freight.
- First-year utilization estimate: Management pegs first-year utilization of new capacity at ~30%, calling 50% "very optimistic" and "tough" but "doable."
- Two-year target: Over the next two years, management expects to achieve ~70–80% utilization of the expanded MCC capacity.
- Current utilization near ceiling: The company is operating at 94% capacity utilization; at 90% it already starts fine-tuning and debottlenecking to pull in an additional 5–7% capacity.
- Post-expansion debottlenecking: After achieving full capacity on the expanded base, the company can add another 25% capacity over time through debottlenecking, not immediately.
- Revenue from current capacity: With product mix and specialized products, top line can go up even more than ₹70–80 Cr quarterly, with a 20–25% growth rate while maintaining bottom line.
Amit Raj Sinha: "At this moment our focus is to see that the execution of the CAPEX gets done as fast as possible. ... in terms of utilizing of all this added capacity over two years we still stand by it, but is very difficult to give a firm commitment on this because there is outside situation, there are lot of other variables which come in. ... maybe the two years might change to three-year period, but on a positive note I believe that we should be able to absorb a major chunk of the added capacity over the next two years."
Diversification Bets: Nutraceuticals, CCS & Healthcare
- Nutritional premix plant operational: The 9,000 MT facility taken on a 10-year lease has been commissioned; sampling is out to customers and business development is underway.
- Nutraceutical revenue guidance cut: Earlier guidance of ₹18–20 Cr for H2 FY23 has been revised down to ₹12–15 Cr; management describes the segment as "very initial stages."
- Meaningful revenue distant: Management expects meaningful revenue from the food and nutrition division in the next two years, with more clarity possibly by end of the current financial year.
- CCS plant timeline: EC clearance is expected in 6–12 months; post-clearance, a lead time of 15–18 months is needed to get the project up and running, meaning no revenue in the current financial year.
- CCS capacity and margin target: The greenfield CCS plant is planned for 1,800 MT per annum; management believes Sigachi can match the competitive EBITDA profile of 25–30%.
- OTC healthcare launch underway: Distribution system and marketing setup are in progress; advertisements in local newspapers and on television have been running for two OTC products in North and Eastern India over the last month and a half.
- Dubai subsidiary incorporated: A marketing office to strengthen sales in the Middle East and Africa; no manufacturing facilities planned; currently stabilizing and hiring the team.
- Kurnool land in limbo: Possession of 25 acres has been taken, but the earlier ethanol project was scrapped; the company is still deliberating on the most optimum project aligned with market needs and competencies.
Amit Raj Sinha: "EC clearance expected timelines anything what we speak is we cannot be very sure, but I personally expect that it should get on an earlier note, it should get done within 6 months, if it is get on a delayed note it might get done within 12 months."
O&M Business & Strategic Positioning
- O&M is a CAPEX-light growth vector: Management is very bullish on the O&M segment because it does not involve CAPEX; the Aditya Birla group contract indicates Sigachi is executing their plant better and more cost-effectively than they had been doing themselves.
- Growth trajectory: Good growth is expected in the O&M segment going forward, though management said it is "very difficult to quantify" the path to ₹100 Cr plus in three years.
- Value chain migration thesis: Management sees Sigachi gradually moving up the value chain in its product basket and value-added offerings to customers, which it expects will improve pricing power and margins over time.
- Product replacement risk low: Management argues the risk component in the MCC category is extremely low because all products are proven Pharmacopoeial products, incorporated many years back and approved for use.
- No backward integration: Management ruled out backward integration into pulp mills, citing CAPEX requirements of thousands of crores that are not scalable or possible for their line of activity, especially given competitively priced, sustainability-certified pulp availability.
- Acquisitions on radar but distant: Management acknowledged positive thoughts on acquisitions but said it is very early to look at anything concrete.
Amit Raj Sinha: "I am actually very bullish on the O&M part of our business. One of the prime reasons is that it does not involve the CAPEX. It is a service industry and in the service industry I can show my results upfront."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| New MCC capacity commissioning | 7,000 MT brownfield expansion at Dahej and Jhagadia ready; commissioning activity to commence | Q4 FY23 |
| New MCC capacity first sales | Sales from new capacity to start showing | Q1 FY24 |
| New MCC capacity absorption | ~70–80% utilization of expanded capacity | Over next two years (could extend to three) |
| First-year utilization of new MCC capacity | ~30% utilization | First year post-commissioning |
| Nutraceutical revenue | ₹12–15 Cr | H2 FY23 |
| CCS plant EC clearance | Environmental clearance for croscarmellose sodium plant | 6–12 months |
| CCS plant commercialization | Revenue to begin post 15–18 month lead time after EC clearance | Next financial year (FY24) |
| Tax rate | 18–20% guided rate | FY23 |
| Lower tax rate duration | 11% rate from deferred tax assets continues | Another 4 years until SEZ exemption lapses |
| Depreciation run-rate | ~₹2.1 Cr quarterly | At least through H2 FY23 until new plant operational |
| EBITDA margin floor | Above 20–21% irrespective of realization changes | Ongoing |
| Q3 price increase | Single-digit price rise for some customers | Q3 FY23 |
| Post-expansion debottlenecking | Additional 25% capacity on expanded base | Over a period of time, not immediately |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Operational income | ₹83 cr, +44.2% YoY |
| EBITDA | ₹16 cr, +~21% YoY |
| EBITDA margin | 19.76% |
| Net profit after tax | ₹14 cr, +37.4% YoY |
| PAT margin | 16.48%, -82 bps YoY |
| Volume growth | ~8.5% YoY |
| Realization growth | 25% YoY |
| Sales volume | ~3,500 metric tons |
| Capacity utilization | 94.5% |
| Export sales (H1 FY23) | ₹113.2 cr, +40% vs ₹80.87 cr in H1 FY22 |
| Raw material cost | $900–$950, vs ~$850 in Q1 and ~$650 YoY |
| Average selling price | ₹217.04, vs ₹216.75 in Q1 |
| O&M revenue (FY23 expectation) | ~₹25 cr, vs ₹13.5 cr in FY22 |
| O&M EBITDA margin | ~22% |
| Nutraceutical revenue (H1 FY23) | Less than ₹1 cr |
| Nutraceutical revenue (FY23 guidance) | ₹12–15 cr, revised from ₹18–20 cr |